Wed. 21 Feb 2024, 2:05am ET
Benzinga
Earnings, News
Calliditas Therapeutics (NASDAQ:CALT) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.07) by 8.57 percent. This is a 392.31 percent decrease over losses of $(0.01) per share from the same period last year. The company reported quarterly sales of $42.41 million which beat the analyst consensus estimate of $35.86 million by 18.27 percent. This is a 5.19 percent increase over sales of $40.32 million the same period last year.